Understand testosterone reference intervals, the 264 and 300 ng/dL cutoffs, and why assay methods and clinical context matter near a threshold.
A testosterone reference range is an interval describing results in a defined comparison population. A clinical decision threshold is a concentration used to help guide clinical assessment. These serve different purposes: the reference interval describes where a result sits relative to a group, while the threshold helps a clinician interpret it in a particular medical context.
This article is for informational purposes and is not medical advice. A qualified clinician should interpret individual results and make decisions about diagnosis or treatment.
A testosterone report brings together several pieces of information: the measured concentration, the laboratory’s reference interval and sometimes a flag indicating that the result falls outside that interval. None of these establishes a diagnosis by itself. The research discussed here concerns total testosterone measured in blood.
The biological measurement is a hormone concentration. The reference interval places that concentration within a selected population’s results. It is not a direct measurement of symptoms or a statement about whether treatment is appropriate.
This distinction matters when someone treats the lower boundary of a laboratory interval as a universal dividing line between health and disease. A reference interval belongs to the population and measurement system used to establish it. A clinical threshold has a separate purpose and must be interpreted in its clinical context.
Our explanation of reading laboratory results without overinterpreting the interval addresses that distinction in more detail.
As summarized in a Clinical Chemistry study, the Endocrine Society’s 2018 guideline uses a morning total testosterone concentration below 264 ng/dL (9.2 nmol/L) together with relevant clinical scenarios. The concentration and the clinical circumstances belong together. Removing the second part changes the meaning of the recommendation.
The same article explains that the 264 ng/dL figure was established from large study cohorts whose measurement methods were standardized through the CDC’s Hormone Standardization program. That history matters because the figure was not created independently of laboratory measurement quality or the populations studied.
A different approach appears in Mito Health’s summary of American Urological Association guidance. It describes total testosterone below 300 ng/dL as a reasonable cutoff supporting diagnosis. That summary also says low values should be accompanied by symptoms or signs.
These figures are guideline-linked decision aids rather than interchangeable definitions of “normal.” Neither supplies a complete laboratory reference interval. Neither establishes an upper reference limit or a personal treatment target.
For a result near a cutoff, the useful question is not simply which number is correct. It is which framework the clinician is applying and how the laboratory result fits the man’s clinical circumstances. Presenting either threshold without those qualifications creates more certainty than the evidence supports.
The central Clinical Chemistry study examined accuracy-based proficiency testing for testosterone. This type of study evaluates laboratory measurement performance using test samples. It helps show why a numerical threshold needs to be considered alongside the method producing the result.
The authors explain that assay bias and imprecision can affect classification near the 264 ng/dL decision point. In plain language, differences in measurement performance may influence which side of a threshold a sample’s reported result falls on. That does not mean every result near the threshold is inaccurate.
The study documented meaningful differences between method groups around the clinical threshold. Its practical message is that the test method is part of the interpretation. A number should not be separated from the measurement process that produced it.
The study also has defined limits. Its sample findings are not estimates of how often patients are misclassified in routine care. The authors noted sample-selection concerns and reported that formal commutability studies were not performed on the survey aliquots. Those studies would help establish whether the survey material behaved like genuine patient samples across methods.
These findings support attention to assay performance. They do not support assuming that all laboratories are unreliable or that a particular patient’s diagnosis is wrong.
The guideline-linked approaches described above connect a low concentration with relevant clinical circumstances or symptoms and signs. An out-of-range flag is therefore not a substitute for clinical assessment. Equally, a symptom does not establish a low testosterone concentration.
The laboratory study was not a study of symptom patterns in adult men. Its findings do not establish which complaints would identify a concentration below or above a reference interval. They should not be used to build a symptom checklist for diagnosing either low or high testosterone.
The useful clinical discussion concerns what the man is experiencing and how those concerns fit with the laboratory findings. A result inside an interval does not itself explain a complaint. A result outside it does not establish that testosterone is the cause.
Testostra’s guide to considering symptoms alongside a low result provides related context for that conversation.
Screening is a separate question. In its 2026 statement, the Endocrine Society said evidence is insufficient to support population-level testosterone screening for hypogonadism in asymptomatic men. That statement does not mean testing is never appropriate without symptoms. It also does not establish a new universal reference range.
A difference between reported testosterone results is not automatically evidence of a biological change. The Clinical Chemistry study shows why analytical performance must also be considered. Identifying a measurement issue and identifying a physiological cause are different tasks.
The study evaluated laboratory testing rather than the effects of nutrition or environmental exposure on testosterone. Its findings should not be turned into a diet recommendation or a lifestyle prescription. They also do not establish which physiological factors explain an individual man’s result.
For a near-cutoff result, the evidence supports reviewing these inputs to interpretation:
These are interpretation inputs rather than proven lifestyle causes of low testosterone. Keeping those categories separate avoids attributing an analytical difference to a biological problem without supporting evidence.
Confirmation is another question for the clinician. The primary study does not specify how many repeat tests should be performed or which repeat method should be used. It therefore supports discussing confirmation without supplying a personal testing protocol.
For that discussion, the useful issue is whether the result needs further assessment in its clinical context. Our guide to putting an initial low measurement in perspective offers related educational background.
“Which reference interval and assay apply to my result? Which clinical threshold are you using and why? How do my symptoms or signs affect its interpretation? Is confirmation appropriate before drawing a diagnostic conclusion or discussing treatment?”
A precise-looking testosterone number can leave the meaning of the test unsettled. Testostra addresses confusion about total testosterone, free testosterone and SHBG through readable hormone education that places biomarkers in context and distinguishes research findings from personal medical decisions. Its coverage helps readers bring clearer questions about related tests to a qualified clinician.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra